Literature DB >> 4031497

Antibody-independent activation of C1, the first component of complement, by cardiolipin.

T Kovacsovics, J Tschopp, A Kress, H Isliker.   

Abstract

Lipid vesicles containing phospholipids known to be present in substantial amounts in mitochondrial membranes were tested for their capacity to activate C1. Among them, only cardiolipin (CL) was highly efficient in C1 activation; no such effect was observed with phosphatidylcholine, phosphatidylethanolamine, or phosphatidylinositol. CL was shown to bind specifically C1q, because only unlabeled C1q competed with 125I-C1q for binding to CL. The requirement for C1q was confirmed by the finding that only fully reconstituted macromolecular C1, containing C1q, was activated by CL. The specificity of CL-induced activation of C1 was also demonstrated by introducing adriamycin, an agent known to interact with CL. Whereas adriamycin did not decrease C1 activation induced by immune complexes, it abrogated C1 activation by CL. The latter was shown to be a strong nonimmune activator of C1, because C1-INH did not inhibit CL-induced activation. When the concentration of CL in vesicles was decreased in the presence of phosphatidylcholine, C1 activation was detected only above a critical level of 35 mol% CL, compatible with a minimal density or clustering of CL molecules in the plane of the membrane. Moreover, C1 activation by CL was modulated by the addition of cholesterol. The threshold of CL required for C1 activation was lowered by the incorporation of more than 35 mol% cholesterol into the vesicles. These results show that CL incorporated into liposomes can be a potent nonimmune activator of C1. The negatively charged phosphate groups in CL are likely candidates for Clq-binding.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031497

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation.

Authors:  C Mold; C A Morris
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

2.  Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction.

Authors:  T Tada; H Okada; N Okada; H Tateyama; H Suzuki; Y Takahashi; T Eimoto
Journal:  Virchows Arch       Date:  1997-04       Impact factor: 4.064

3.  Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis.

Authors:  T S Halstensen; T E Mollnes; P Garred; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

4.  Complement activation by anticardiolipin antibodies.

Authors:  M B Santiago; N Gaburo; R M de Oliveira; W Cossermelli
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

Review 5.  The role of complement in danger sensing and transmission.

Authors:  Jörg Köhl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.

Authors:  Hee Young Hwang; Marcus R Duvall; Stephen Tomlinson; Robert J Boackle
Journal:  Mol Immunol       Date:  2008-03-03       Impact factor: 4.407

Review 7.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

8.  Interaction of Neisseria gonorrhoeae with classical complement components, C1-inhibitor, and a monoclonal antibody directed against the Neisserial H.8 antigen.

Authors:  J E Schweinle; P J Hitchcock; A J Tenner; C H Hammer; M M Frank; K A Joiner
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

9.  C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.

Authors:  Regina Tavano; Luca Gabrielli; Elisa Lubian; Chiara Fedeli; Silvia Visentin; Patrizia Polverino De Laureto; Giorgio Arrigoni; Alessandra Geffner-Smith; Fangfang Chen; Dmitri Simberg; Giulia Morgese; Edmondo M Benetti; Linping Wu; Seyed Moein Moghimi; Fabrizio Mancin; Emanuele Papini
Journal:  ACS Nano       Date:  2018-05-23       Impact factor: 15.881

10.  The specificity of anti-cardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus.

Authors:  S Mouritsen; M Høier-Madsen; A Wiik; O Orum; N Strandberg Pedersen
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.